Epidermal Growth Factor Receptor as a Target for Anti-Cancer Agent Design

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)


Volume 16, 12 Issues, 2016


Download PDF Flyer




Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Epidermal Growth Factor Receptor as a Target for Anti-Cancer Agent Design



Anti-Cancer Agents in Medicinal Chemistry, 10(6): 491-503.

Author(s): Jiangying Cao, Hao Fang, Binghe Wang, Chunhua Ma and Wenfang Xu.

Affiliation: Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong, University, Jinan 250012, P.R. China.

Abstract

The epidermal growth factor (EGF) receptors, one family of protein tyrosine kinases (PTK), are promising targets for the cancer therapy. Many potential inhibitors including monoclonal antibodies (mAbs), reversible inhibitors and irreversible inhibitors have been developed. Some of them have been approved by the FDA or in the stage of clinical trials. This report reviews the recent progress of the structures, functions and inhibitors of the epidermal growth factor receptor tyrosine kinases.

Keywords:

EGFR, epidermal growth factor receptor, protein tyrosine kinase, receptor tyrosine kinase, structure activity relationship, Anti-Cancer Agent, epidermal growth factor (EGF) receptors, protein tyrosine kinases, cancer therapy, monoclonal antibodies, cysteine-rich domains, α-and β-phosphates, DFG aspartate residue, DFG phenylalanine residue, Lapatinib, sorafenib, erlotinib, EGFR kinase, CDK2, transforming growth factor-α, amphiregulin, heparin-binding EGF, neuregulins, breast caner, mitogen-activated protein kinase (MAPK) pathway, phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB/AKT) pathway, signal transducer and activator of transcription (STAT) pathway, phospholipase C pathway and SRC/FAK pathway, avian erythroblastosis tumor, Autocrine-paracrine stimulation, umor necrosis factor-α(TGF-α), Cetuximab, Erbitux, Trastuzumab, Herceptin, Pertuzumab, Quinazoline Scaffold, Gefitinib, anilinoquinazoline scaffold, Alkynyl Pyrimidine Scaffold, Pyrrolotrizaine Scaff, Thiazolopyrimidine Scaffold, Quinoline-3-Carbonitrile Scaffold, Benzylidene Hydantoin Scaffold, 4-Amino-6-Arylaminopyrimidine-5-Carbaldehyde Oximes Scaffold, 4-Amino-6-Arylaminopyrimidine-5-Carbaldehyde Hydrazones Scaffold, 5-Oxadiazol-4,6-Diaminopyrimidines Scaffold, 5,7-Diazaindolinone Scaffold, Thiazolidinone Scaffold, Imidazothiazole Scaffold, Histone Deacetylases (HDACs), Pyrrolpyrimidine Scaffold, Acrylamide Scaffold, 1,2-Dithiolane Scaffold, Prrolidinyl-Acetylenicthienopyrimidine Scaffold.



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 10
Issue Number: 6
First Page: 491
Last Page: 503
Page Count: 13
DOI: 10.2174/1871520611009060491
Price: $58
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science